Cargando…
Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab—A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach
Systemic lupus erythematosus (SLE) is a clinically heterogeneous autoimmune disease, and organ manifestations, such as lupus nephritis (LN) or skin disease, may be refractory to standard treatment. Therefore, new agents are required to allow for a more personalized therapeutic approach. Recently, se...
Autores principales: | Plüß, Marlene, Piantoni, Silvia, Wincup, Chris, Korsten, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225134/ https://www.ncbi.nlm.nih.gov/pubmed/35743519 http://dx.doi.org/10.3390/jcm11123449 |
Ejemplares similares
-
Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022) -
Anifrolumab for systemic lupus erythematosus
Publicado: (2022) -
Role of Anifrolumab in Refractory Cutaneous Manifestations of Lupus Erythematosus: A Case Series and Literature Review
por: Khan, Muhammad Atif, et al.
Publicado: (2023) -
Anifrolumab for Adolescent Discoid Lupus Erythematosus
por: Shaw, Katharina S., et al.
Publicado: (2023) -
OA14 The role of anifrolumab in treating life threatening systemic lupus erythematosus with severe mucocutaneous involvement
por: Baldwin, Christopher, et al.
Publicado: (2023)